Clinical Trials in Netherlands, 2026

Trials with a site in Netherlands

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase II

A phase 2 study to assess efficacy of induction Enfortumab Vedotin plus Pembrolizumab using a response-adapted approach to spare the bladder: FIDELIO

2026-525965-29-00Adult patients with cT2-4aN0-1 urothelial bladder cancer, w…

DrugsEnfortumab Vedotin·Pembrolizumab

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

05/10/2026

Phase III

A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)

2025-524067-20-00Primary Biliary Cholangitis (PBC)

DrugSaroglitazar Magnesium

Zydus Therapeutics Inc.

Digestive System Diseases

Greece, Netherlands, Spain

05/10/2026

Phase III

A randomized, double-blind, placebo-controlled, 2-arm multicenter Phase III study to assess the efficacy and safety of ianalumab in participants with Sjogren's disease with high symptom burden (THALASSA)

2025-522271-29-00Sjögren's disease

DrugsTenofovir Alafenamide·Entecavir·Ianalumab

Novartis Pharma AG

Immune System Diseases

Slovakia, France, Netherlands

05/10/2026

Phase IV

Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial

2025-524593-42-00Rheumatoid Arthritis

DrugsCertolizumab Pegol·Abatacept·Sarilumab·Etanercept

Universiteit Leiden

Musculoskeletal Diseases

Netherlands

05/10/2026

Phase I/II

A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC

2026-525634-27-00Extrapulmonary neuroendocrine carcinoma of large cell histo…

DrugsZL-1310·Obrixtamig·Tocilizumab·Atezolizumab

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

France, Belgium, Netherlands

05/10/2026

Phase IV

A long-term prospective monitoring study of all patients with Pompe Disease. Evaluating natural history, treatment response, disease markers and novel outcome measures.

2024-520365-31-01Pompe disease / glycogenosis type II / acid maltase deficie…

DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Nutritional and Metabolic Diseases

Netherlands

01/10/2026

Phase I

Human study to evaluate how NDI-225673 works and to determine an appropriate dose

2026-527578-35-00Inflammatory bowel disease

Nimbus Salacia Inc.

Immune System Diseases

Netherlands

30/09/2026

Phase II

PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)

2026-526261-14-00Immune-related Colitis or Hepatitis with Inadequate Respons…

DrugsAzathioprine·Vedolizumab·Infliximab

Therakos Europe Limited

Neoplasms

Austria, Spain, Italy, Germany, Netherlands

30/09/2026

Phase I/II

A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements

2026-526409-14-00Acute Myeloid Leukemia

DrugsPosaconazole·Daunorubicin·Cytarabine·Azacitidine

Charm Therapeutics Limited

Neoplasms

France, Germany, Spain, Poland, Netherlands

30/09/2026

Phase III

A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)

2025-521617-97-00Atrial Fibrillation (AF)

DrugsCenvacibart·Apixaban

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania

29/09/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)

2026-525622-37-01Phenylketonuria

Maze Therapeutics Inc.

Nutritional and Metabolic Diseases

Germany, France, Netherlands

29/09/2026

Phase III

A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)

2025-521618-25-00Atrial Fibrillation (AF)

DrugsAmrecibart·Cenvacibart

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Spain, Bulgaria, Hungary, Poland, Romania, Sweden, Germany, Italy, Latvia, Netherlands, Portugal

29/09/2026

Phase III

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

2025-522954-37-00Peripheral Artery Disease

DrugsAmrecibart·Cenvacibart·Rivaroxaban

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands

29/09/2026

Phase I

A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol

2025-524595-37-00Systemic lupus erythematosus (SLE)

DrugsDiphenhydramine·Epinephrine·Paracetamol

UCB Biopharma

Immune system processes

Greece, Italy, Netherlands, Austria, Belgium, Sweden, Spain, Denmark, Germany

28/09/2026

Phase IV

Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus

2026-525910-77-00Post-transplantation Diabetes Mellitus

DrugsGlucagon·Semaglutide

Radboud universitair medisch centrum Stichting

Hormonal diseases

Netherlands

28/09/2026

Phase I

[¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas

2026-526106-32-00Glioblastoma

Universitair Medisch Centrum Groningen

Nervous System Diseases

Netherlands

28/09/2026

Phase III

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

2025-522648-42-01• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent …

DrugsAtumelnant·Hydrocortisone

Crinetics Pharmaceuticals Inc.

Not possible to specify

Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France

28/09/2026

Phase I

Drug-drug interaction study of midazolam and brensocatib

2026-526670-16-00Non-Cystic Fibrosis Bronchiectasis

Insmed Inc.

Respiratory Tract Diseases

Netherlands

28/09/2026

Phase III

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.

DrugDanicamtiv

Kardigan Inc.

Cardiovascular Diseases

Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands

28/09/2026

Phase III

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

2026-525886-38-00Inherited retinal dystrophy due to dysfunction in the human…

Atsena Therapeutics Inc.

Eye Diseases

Italy, Germany, Spain, Netherlands, France, Belgium

28/09/2026

Phase III

SHING-ID: Fractional dose shingles vaccination

2026-526934-16-00Shingles

Leids Universitair Medisch Centrum (LUMC)

Virus Diseases

Netherlands

28/09/2026

Phase I

[14C]Navlimetostat Mass Balance Study in Healthy Female Participants

2026-527504-24-00Advanced Solid Tumors

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Netherlands

24/09/2026

Phase I

A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA

2026-525574-19-00Amyotrophic Lateral Sclerosis

Eli Lilly & Co.

Nervous System Diseases

Netherlands, Belgium, Germany, Spain

22/09/2026

Phase II

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease

2026-525197-19-00Fibrostenosing Crohn’s Disease

DrugOntunisertib

Agomab Spain S.L.U.

Digestive System Diseases

France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands

21/09/2026

Phase III

A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease

2025-524464-38-00Sickle cell disease

Novo Nordisk A/S

Hemic and Lymphatic Diseases

France, Netherlands, Spain, Italy

21/09/2026

Phase III

A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy

2025-523362-25-00Neoplasms, Endometrial

DrugsDoxorubicin·Paclitaxel

Glaxosmithkline Research & Development Limited

Neoplasms

Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia

21/09/2026

Phase III

A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.

2025-523361-25-00Ovarian Neoplasms

DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab

Glaxosmithkline Research & Development Limited

Neoplasms

Denmark, Austria, France, Sweden, Finland, Netherlands, Norway, Czechia, Belgium, Greece, Italy, Germany, Spain

21/09/2026

Phase I

A Phase 1, non-randomized, fixed-sequence, multiple-dose study investigating the drug drug interaction potential and QTc effects of fosmanogepix in healthy adult subjects.

2026-526076-23-00Invasive fungal infections (IFIs)

Basilea Pharmaceutica International AG Allschwil

Not possible to specify

Netherlands

21/09/2026

Phase II

Learning From Early Aficamten In HCM (LEAF-HCM)

2025-523090-42-00Hypertrophic cardiomyopathy

DrugsAficamten·[68Ga]Ga-FAPI-46

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cardiovascular Diseases

Netherlands

21/09/2026

Phase II

A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

2026-526177-42-00Infections and infestations

Sanofi Vaccines US Inc.

Virus Diseases

Estonia, Spain, Germany, Czechia, Poland, Finland, Netherlands

21/09/2026

Phase II

A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus.

2025-524578-41-00Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca AB

Immune System Diseases

Belgium, Portugal, Netherlands

21/09/2026

Phase II

Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)

2025-524469-25-00chronic advanced heart failure with reduced ejection fracti…

AnaCardio AB

Cardiovascular Diseases

Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary

21/09/2026

Phase III

A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)

2025-524493-42-00Idiopathic Pulmonary Fibrosis

DrugsDeupirfenidone·Pirfenidone

Puretech Lyt 100 Inc.

Respiratory Tract Diseases

Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands

18/09/2026

Phase III

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

2025-524202-15-00Recurrent Platinum-Sensitive Ovarian Cancer

DrugsPegfilgrastim·Doxorubicin·Paclitaxel·Bevacizumab

Genmab A/S

Neoplasms

Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland

18/09/2026

Phase III

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)

2025-524405-33-00Choroidal Melanoma

Aura Biosciences Inc.

Neoplasms

Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy

17/09/2026

Phase III

Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)

2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria

16/09/2026

Phase III

A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

2026-526654-14-01Newly Diagnosed Multiple Myeloma

DrugsRamantamig·Velcade·Bortezomib·Daratumumab

Janssen Cilag International

Neoplasms

Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain

16/09/2026

Phase III

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis

2025-522393-37-00Autoimmune Hepatitis (AIH)

DrugInebilizumab

Amgen Inc.

Digestive System Diseases

Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain

16/09/2026

Phase I

A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer

2025-522707-26-00Advanced HR+/HER- breast cancer

Novartis Pharma AG

Neoplasms

Germany, France, Netherlands, Spain, Italy

15/09/2026

Phase I/II

A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity

2026-526797-16-00Obesity and overweight

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands

14/09/2026

Phase II

Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial

2026-525680-41-00Vascular Calcification

Radboud universitair medisch centrum Stichting

Therapeutics

Netherlands

11/09/2026

Phase I

Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

2025-521143-20-00Bone Morphogenic Protein Receptor type 2 mutation carriers …

Amsterdam UMC Stichting

Diagnosis

Netherlands

10/09/2026

Phase III

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)

2026-525489-23-00Relapsed Extensive-Stage Small Cell Lung Cancer After Plat…

DrugsSiltuximab·Tarlatamab

Amgen Inc.

Neoplasms

Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain

08/09/2026

Phase I

A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

2026-525215-13-00Advanced Solid Tumors

F. Hoffmann-La Roche AG

Neoplasms

Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France

07/09/2026

Phase I

A Phase 1 study of a novel sublingual insulin formulation

2025-521863-11-00Type 1 diabetes mellitus

Sublin B.V.

Metabolism

Netherlands

04/09/2026

Phase II

Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)

2026-526545-95-00Reactive aggression

DrugPropranolol

Radboud universitair medisch centrum Stichting

Behavior and Behavior Mechanisms

Netherlands

02/09/2026

Phase III

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

2026-525913-30-00Immune system diseases

DrugsBelumosudil·Ixazomib·Imatinib·Sirolimus

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark

02/09/2026

Phase II

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Eye Diseases

Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal

01/09/2026

Phase II

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

2026-525848-15-00GBA1-associated Parkinson’s disease

Vanqua Bio Inc.

Nervous System Diseases

Netherlands, France, Spain, Germany

01/09/2026

Phase IV

Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study

2026-526348-11-01Eosinophilic Esophagitis

DrugDupilumab

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

01/09/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium

31/08/2026

Phase II

In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint

2026-526251-60-00Unresectable stage III non-small cell lung cancer

DrugDurvalumab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

31/08/2026

Phase II

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

2025-524230-25-00Diffuse large B-cell lymphoma (DLBCL)

DrugsEpcoritamab·Rituximab

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway

31/08/2026

Phase I/II

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…

DrugPosaconazole

Institut De Recherches Internationales Servier IRIS

Neoplasms

Netherlands, Spain, Germany, Italy, France, Finland

27/08/2026

Phase II

MDMA-assisted therapy for adolescents with treatment-resistant PTSD

2024-515184-65-01Post-traumatic stress disorder

Stichting Amsterdam UMC

Mental Disorders

Netherlands

26/08/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)

Contineum Therapeutics Inc.

Respiratory Tract Diseases

Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain

26/08/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

2025-524130-26-00Gastrointestinal Cancers

DrugPegfilgrastim

Genmab A/S

Neoplasms

Italy, Belgium, France, Spain, Denmark, Netherlands, Germany

26/08/2026

Phase II

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

2025-524905-34-00Solid tumor

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania

25/08/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

2025-524928-21-00Pancreatic Adenocarcinoma

DrugRMC-9805

Revolution Medicines Inc.

Neoplasms

Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark

24/08/2026

Phase II

A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy

2026-525896-23-00Focal epilepsy

Ovid Therapeutics Inc.

Nervous System Diseases

Netherlands

21/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

2025-524934-24-00Neoplasms, Gastrointestinal Stromal

DrugImatinib

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary

21/08/2026

Phase I

A study to see how safe a new medicine (NNC0705-0002) is in healthy people

2026-526205-15-00Cardiometabolic

Novo Nordisk A/S

Not possible to specify

Netherlands

21/08/2026

Phase I

A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)

2025-524555-31-00Recurrent Glioblastoma

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Nervous System Diseases

Netherlands

21/08/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

2025-525102-38-00Elevated lipoprotein(a)

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Netherlands, Denmark, Germany, Spain

18/08/2026

Phase III

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

2026-525513-31-00Small-cell lung cancer, limited stage

DrugDurvalumab

Norges Teknisk-Naturvitenskapelige Universitet NTNU

Neoplasms

Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands

17/08/2026

Phase II

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

2025-525033-31-00heart failure

DrugCRD-4730

Cardurion Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia

14/08/2026

Phase I/II

Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)

2025-524046-10-00Lynch Syndrome

Radboud universitair medisch centrum Stichting

Digestive System Diseases

Netherlands

12/08/2026

Phase I

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

2025-524805-34-00Locally Advanced or Metastatic Solid Tumors

Exelixis Inc.

Neoplasms

Italy, Netherlands, France, Spain

11/08/2026

Phase I

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

2025-522532-14-00Advanced solid tumors

Pfizer Inc.

Neoplasms

Netherlands, France, Spain

11/08/2026

Phase I/II

Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity

2026-525353-37-00Plasmodium falciparum malaria

Leids Universitair Medisch Centrum (LUMC)

Parasitic Diseases

Netherlands

10/08/2026

Phase III

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

2025-524626-18-00Overweight and obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden

10/08/2026

Phase II

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

2025-523807-31-00Atrial fibrillation

Bayer AG

Cardiovascular Diseases

Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria

06/08/2026

Phase III

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…

DrugBenralizumab

AstraZeneca AB

Respiratory Tract Diseases

Denmark, Belgium, France, Italy, Netherlands, Austria, Poland

04/08/2026

Phase II

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

2025-525016-41-00Idiopathic Pulmonary Fibrosis

AstraZeneca AB

Respiratory Tract Diseases

Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark

04/08/2026

Phase III

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

2025-523884-39-00Systemic sclerosis

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Skin and Connective Tissue Diseases

Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania

03/08/2026

Phase II

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

2026-527114-23-00Epilepsy

Ovid Therapeutics Inc.

Nervous System Diseases

Netherlands

03/08/2026

Phase III

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

2026-525922-39-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece

03/08/2026

Phase III

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

2026-525923-26-00Moderately to Severely Active Ulcerative Colitis

DrugsJNJ-78934804·Guselkumab

Janssen Cilag International

Immune System Diseases

France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal

03/08/2026

Phase I

Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

2026-525568-17-00HER2 mutation positive NSCLC

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Pathological Conditions, Signs and Symptoms

Netherlands

30/07/2026

Phase I

Nav 1.8 and 1.7 combo trial

2026-526867-39-00Pain

Niroda Therapeutics Inc.

Nervous System Diseases

Netherlands

30/07/2026

Phase III

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

2025-524858-34-00Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases

Eli Lilly & Co.

Cardiovascular Diseases

Hungary, Czechia, Spain, Netherlands

30/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …

DrugsElecoglipron·Dapagliflozin

AstraZeneca AB

Cardiovascular Diseases

Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia

29/07/2026

Phase III

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

2025-522488-14-00Participants with obesity with or without type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium

27/07/2026

Phase III

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

2025-523837-25-00Barth Syndrome

DrugElamipretide

Stealth Biotherapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Netherlands, France, Italy

27/07/2026

Phase III

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

2024-516251-40-01Atrial Fibrillation

Milestone Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands

27/07/2026

Phase IV

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

2026-526289-25-00Parapneumonic pleural infection/pleural empyema

DrugsDornase Alfa·Alteplase

Amsterdam UMC Stichting

Therapeutics

Netherlands

24/07/2026

Phase IV

Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

2026-525909-13-00Diabetes

DrugsPneumococcal Vaccine·Liraglutide

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

22/07/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…

DrugMivelsiran

Alnylam Pharmaceuticals Inc.

Nervous System Diseases

Italy, Netherlands, Spain, Germany, Ireland

22/07/2026

Phase III

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

2026-525242-29-00Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen Bioscience Inc.

Digestive System Diseases

Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway

21/07/2026

Phase I/II

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

2025-523874-17-00Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

Neoplasms

Netherlands, France, Spain

21/07/2026

Phase I

A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen

2026-526209-13-00Gastric Cancer, Esophageal cancer

DrugCapecitabine

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

2025-524336-19-00HIV-1

DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF

Gilead Sciences Inc.

Virus Diseases

Poland, Italy, France, Spain, Germany, Netherlands

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

2025-524335-39-00HIV-1

DrugsZinlirvimab·Rilpivirine·Cabotegravir·Lenacapavir

Gilead Sciences Inc.

Virus Diseases

Netherlands, Poland, Germany, France, Spain, Italy

21/07/2026

Phase II

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

2025-524842-89-00chronic lymphocytic leukemia (CLL) and small lymphocytic ly…

DrugsEpcoritamab·Pirtobrutinib

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasms

Netherlands

20/07/2026

Phase III

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

2025-522227-99-00Huntington’s Disease

DrugVotoplam

Novartis Pharma AG

Nervous System Diseases

Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary

20/07/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-524711-36-00Narcolepsy Type 1

DrugALKS 2680

Alkermes Inc.

Nervous System Diseases

Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland

20/07/2026

Phase III

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

2025-523662-24-00Homozygous Familial Hypercholesterolemia (HoFH)

DrugZodasiran

Arrowhead Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Denmark, Norway, Sweden, Poland

20/07/2026

Phase II

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

2025-523617-29-01Oral cavity squamous cell carcinoma

DrugsIpilimumab·Nivolumab

Amsterdam UMC Stichting

Neoplasms

Netherlands

17/07/2026

Phase III

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

2025-524648-37-00Metastatic colorectal cancer

Merck Healthcare KGaA

Neoplasms

Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria

14/07/2026

Phase III

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

2025-525088-34-00Metastatic Pancreatic Adenocarcinoma

Revolution Medicines Inc.

Digestive System Diseases

Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain

14/07/2026

Phase II

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

2026-525282-50-00Familial Adenomatous Polyposis

Recursion Pharmaceuticals Inc.

Neoplasms

Netherlands, Germany, Spain

13/07/2026

Phase II

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

2025-523293-17-00Cluster headache

Leids Universitair Medisch Centrum (LUMC)

Nervous System Diseases

Netherlands

13/07/2026

Phase II

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

2026-526036-38-00Pleural mesothelioma

DrugUstekinumab

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

09/07/2026

Phase II

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…

DrugEmpasiprubart

Argenx

Immune System Diseases

Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland

08/07/2026

Phase II

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

2026-525260-18-00Multiple Sclerosis

DrugIndapamide

Amsterdam UMC Stichting

Nervous System Diseases

Netherlands

08/07/2026

Phase III

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

2023-505575-69-01Osteosarcoma

DrugCabozantinib

Institut Gustave Roussy

Neoplasms

Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain

08/07/2026

Phase II

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

2025-524967-19-00Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (…

Alnylam Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Sweden, Germany

08/07/2026

Phase I

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

2025-521887-37-00Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal N…

Eli Lilly & Co.

Neoplasms

Germany, Netherlands

07/07/2026

Phase III

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

2025-523369-32-00Fibrosing interstitial lung disease

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Respiratory Tract Diseases

Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal

07/07/2026

Phase II

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

2024-510793-24-00suspected malignant pulmonary disease (lung lesions and/or …

DrugBevacizumab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

06/07/2026

Phase III

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

2024-518213-25-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain

06/07/2026

Phase II

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

2025-521506-17-01Hypoxic-ischemic brain injury (HIBI) because of Perinatal A…

Universitair Medisch Centrum Utrecht

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

06/07/2026

Phase III

Dual-agent fluorescence-guided surgery for colorectal liver metastases

2025-524755-31-00Colorectal liver metastases

Leids Universitair Medisch Centrum (LUMC)

Digestive System Diseases

Netherlands

03/07/2026

Phase I

Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial

2023-507214-28-00Advanced thyroid cancer

Stichting Radboud University Medical Center

Neoplasms

Netherlands

02/07/2026

Phase III

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

2025-521929-32-01First Episode Psychosis (FEP)

DrugCannabidiol

University Of Oxford

Mental Disorders

Netherlands, Greece, Germany, Italy, Austria, Spain

01/07/2026

Phase I

A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis

2026-525220-15-00Plaque Psoriasis

Zealand Pharma A/S

Skin and Connective Tissue Diseases

Netherlands

01/07/2026

Phase I

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

2025-523127-21-00Rheumatoid Arthritis

AbbVie Deutschland GmbH & Co. KG

Immune System Diseases

Belgium, Netherlands, Spain, Germany, Italy

01/07/2026

Phase I

A study in healthy men to test how BI 1815368 is processed in the body

2025-523949-10-00Healthy volunteers trial

Boehringer Ingelheim International GmbH

Not possible to specify

Netherlands

30/06/2026

Phase IV

Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)

2026-525747-33-00unexplained subfertillity, infertillity

DrugProgesterone

Universitair Medisch Centrum Utrecht

Female Urogenital Diseases and Pregnancy Complications

Netherlands

30/06/2026

Phase III

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

2023-508533-14-00Eosinophilic Disease

DrugBenralizumab

AstraZeneca AB

Immune System Diseases

Poland, Netherlands, France

30/06/2026

Phase I/II

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

2025-524791-30-00Non small cell lung cancer

Radboud universitair medisch centrum Stichting

Respiratory Tract Diseases

Netherlands, Germany

29/06/2026

Phase II

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

Immune System Diseases

Netherlands, Romania, Poland, France, Italy, Spain

29/06/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

2025-525009-18-00Pancreatic Ductal Adenocarcinoma

DrugsINCB161734·Fluorouracil·Irinotecan·Oxaliplatin

Incyte Corp.

Neoplasms

Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria

26/06/2026

Phase I

Three-part PK and PD study of AXN-027

2025-524019-35-00Chronic pain, refractory epilepsy, and other neurological d…

Axonis Therapeutics Inc.

Nervous System Diseases

Netherlands

26/06/2026

Phase III

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

2026-526167-38-00liver cirrhosis

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

23/06/2026

Phase II

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2025-523403-29-00Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Spain, France, Netherlands, Germany

23/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia

22/06/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase I/II

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

2025-523111-11-00Amyotrophic lateral sclerosis

Trace Neuroscience Inc.

Musculoskeletal Diseases

Germany, Netherlands

22/06/2026

Phase IV

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

2025-522275-28-00Metachromatic leukodystrophy

Orchard Therapeutics (Europe) Limited

Musculoskeletal Diseases

Netherlands, Germany, Italy, Sweden, France

22/06/2026

Phase II

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

2025-521488-11-00Posttraumatic stress disorder

DrugPsilocybin

ARQ National Psychotrauma Centrum

Mental Disorders

Netherlands

22/06/2026

Phase II

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

2026-525871-24-00Fracture-Related Infection

Amsterdam UMC Stichting

Bacterial Infections and Mycoses

Netherlands

22/06/2026

Phase II

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

2025-522951-24-00Osteogenesis Imperfecta

DrugAGA2115

Angitia Inc. Ltd.

Musculoskeletal Diseases

Netherlands, France, Denmark

22/06/2026

Phase IV

Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.

2025-522900-26-00Post-ERCP Pancreatitis

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

19/06/2026

Phase I

A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity

2026-525179-26-00Cardiometabolic

Novo Nordisk A/S

Not possible to specify

Netherlands

19/06/2026

Phase III

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…

DrugAdmilparant

Bristol-Myers Squibb Services Unlimited Company

Respiratory Tract Diseases

Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany

17/06/2026

Phase I

A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

2026-526279-52-00Healthy volunteers

Arcus Biosciences Inc.

Skin and Connective Tissue Diseases

Netherlands

16/06/2026

Phase II

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

2025-524305-32-00Stage I non-small cell lung cancer

DrugCemiplimab

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Respiratory Tract Diseases

Netherlands

16/06/2026

Phase II

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

2025-525124-10-00Duchenne Muscular Dystrophy

DrugsENTR-601-44·ENTR-601-45

Entrada Therapeutics Inc.

Musculoskeletal Diseases

Belgium, Italy, Netherlands, Spain

16/06/2026

Phase III

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, E…

AstraZeneca AB

Neoplasms

France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands

16/06/2026

Phase I/II

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

2025-520626-37-00Metastatic Prostate Cancer

AstraZeneca AB

Neoplasms

Belgium, Spain, Poland, Italy, Netherlands

16/06/2026

Phase III

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

2025-522643-18-00Stage I NSCLC

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Neoplasms

Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain

16/06/2026

Phase III

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

2024-511296-15-00Musculoskeletal diseases

Sanofi-Aventis Recherche & Developpement

Musculoskeletal Diseases

France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain

15/06/2026

Phase III

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

2025-524371-23-00Limb Girdle Muscular Dystrophy (LGMD) Type 2I

DrugRibitol

ML Bio Solutions Inc.

Musculoskeletal Diseases

Germany, Denmark, Netherlands, Italy, Norway

15/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Netherlands, France, Germany, Spain, Poland, Greece

12/06/2026

Phase III

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

2025-522267-15-00Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

DrugsMK-1045·Blinatumomab·Tocilizumab

Merck Sharp & Dohme LLC

Neoplasms

Greece, Netherlands, Sweden, France, Italy, Spain, Denmark

12/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria

12/06/2026

Phase IV

DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial

2026-525316-33-00Rheumatoid arthritis

Sint Maartenskliniek Stichting

Immune System Diseases

Netherlands

09/06/2026

Phase I/II

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors

Verastem Inc.

Neoplasms

Italy, France, Germany, Belgium, Spain, Netherlands

09/06/2026

Phase III

HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL

2025-524283-38-00Relapsed or refractory small lymphocytic lymphoma, Relapsed…

DrugVenetoclax

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

08/06/2026

Phase II

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

2025-522301-37-00Nonsegmental vitiligo

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, Netherlands, France, Italy

08/06/2026

Phase II

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

2025-524727-41-00Alopecia Areata

Eli Lilly & Co.

Immune System Diseases

Poland, Netherlands

08/06/2026

Phase I/II

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

2025-523497-16-00Lung and/or Liver Disease Associated with Alpha-1 Antitryps…

Tessera Therapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Sweden, Netherlands

08/06/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

2025-522818-23-00Small Cell Lung Cancer (SCLC)

DrugsZL-1310·Topotecan

Zai Lab (US) LLC

Neoplasms

Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France

08/06/2026

Phase II

REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)

2026-526084-38-00Immune Aging, Chronic inflammation

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

08/06/2026

Phase III

A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease

2025-523109-14-00Congenital Heart Disease

Chiesi Farmaceutici S.p.A.

Cardiovascular Diseases

Netherlands, Germany, Portugal, Austria

08/06/2026

Phase I

A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation

2025-523648-11-00adenocarcinoma of the colon or rectum

Bayer Consumer Care AG

Neoplasms

Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium

08/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

2025-523675-39-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Belgium, Greece, Poland, France, Spain, Bulgaria, Italy, Germany, Austria, Netherlands

08/06/2026

Phase IV

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

2025-524741-28-00Severe Asthma

DrugsBenralizumab·Mepolizumab·Tezepelumab·Dupilumab

Amsterdam UMC Stichting

Respiratory Tract Diseases

Netherlands

05/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

2025-523912-35-00Narcolepsy Type 2

Alkermes Inc.

Nervous System Diseases

Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland

04/06/2026

Phase I

T cell imaging in kidney transplantation (TIK)

2025-522490-11-00Renal allograft rejection

Radboud universitair medisch centrum Stichting

Immune system processes

Netherlands

04/06/2026

Phase II

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

2026-525554-11-00Traumatic brain injury

Astrocyte Pharmaceuticals Inc.

Nervous System Diseases

Netherlands

04/06/2026

Phase I/II

A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.

2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)

DrugRiluzole

Nura Bio Inc.

Nervous System Diseases

Poland, Netherlands, Italy, Spain

03/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-523911-13-00Narcolepsy Type 1

Alkermes Inc.

Nervous System Diseases

Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland

02/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

2025-522434-32-00Hemophilia A Without Inhibitors

F. Hoffmann-La Roche AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary

01/06/2026

Phase I

GRAIN, Prospective Pilot Study

2025-524470-41-00Esophageal dysplasia, Barrett's esophagus, Esophageal adeno…

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

01/06/2026

Phase III

Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy

2025-522349-23-00post-COVID syndrome

Amsterdam UMC Stichting

Virus Diseases

Netherlands

01/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

2025-522435-33-00Hemophilia A

F. Hoffmann-La Roche AG

Hemic and Lymphatic Diseases

Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France

01/06/2026

Phase I/II

A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease

2025-524082-25-00Late-Onset Pompe Disease

Denali Therapeutics Inc.

Musculoskeletal Diseases

Germany, Netherlands

01/06/2026

Phase II

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia

DrugsAsparaginase Erwinia chrysanthemi·Tofacitinib·Everolimus·Azacitidine

Centre Hospitalier De Versailles

Hemic and Lymphatic Diseases

Germany, France, Czechia, Netherlands, Spain

29/05/2026

Phase I/II

C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.

2025-523523-21-00Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc.

Neoplasms

Netherlands, Spain

29/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

2025-523555-66-00Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharma AG

Neoplasms

Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France

29/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

2025-523400-72-00Cystic fibrosis

Vertex Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark

29/05/2026

Phase III

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

2025-521590-13-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary

27/05/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

2025-522949-22-00Duchenne muscular dystrophy

Solid Biosciences Inc.

Musculoskeletal Diseases

Spain, Netherlands, France, Italy, Belgium, Germany

26/05/2026

Phase I/II

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

2025-522339-32-00Neoplasm malignant

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia

26/05/2026

Phase I

Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects

2026-525788-42-00Healthy volunteers

Galapagos

Not possible to specify

Netherlands

22/05/2026

Phase I

150 mg CIT-013 phase 1 trial

2026-526153-34-00Immune mediated inflammatory diseases

Citryll B.V.

Immune System Diseases

Netherlands

22/05/2026

Phase III

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland

22/05/2026

Phase II

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

DrugPembrolizumab

Eikon Therapeutics Inc.

Neoplasms

Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland

21/05/2026

Phase I

Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare

2026-525200-99-00Chronic allergic rhinitis

Dianosic

Respiratory Tract Diseases

Netherlands

21/05/2026

Phase I

SAR447971 first-in-human study

2026-525333-22-00Hidradenitis

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Netherlands

20/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

2025-523087-20-00Duchenne muscular dystrophy

DrugAOC 1044

Avidity Biosciences Inc.

Musculoskeletal Diseases

Italy, Germany, France, Spain, Belgium, Poland, Netherlands

20/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

2025-524005-32-00Rheumatoid arthritis

Elevara Medicines Limited

Immune System Diseases

Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain

19/05/2026

Phase III

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…

VarmX B.V.

Hemic and Lymphatic Diseases

Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania

19/05/2026

Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00Proteinuric kidney diseases

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

19/05/2026

Phase II

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer

AstraZeneca AB

Neoplasms

Italy, Spain, France, Netherlands

19/05/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer

DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin

Incyte Corp.

Neoplasms

Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy

19/05/2026

Phase I

A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease

2024-517310-15-00Parkinson's Disease

Mission Therapeutics Limited

Nervous System Diseases

Germany, Netherlands, France

18/05/2026

Phase I

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

2026-525590-40-00human immunodeficiency virus (HIV)

Viiv Healthcare UK Limited

Immune System Diseases

Netherlands

18/05/2026

Phase II

THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation

2025-524541-27-00Hyperinflammation, Sepsis

DrugAnakinra

Prinses Maxima Centrum voor Kinderoncologie B.V.

Immune System Diseases

Netherlands

18/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary

18/05/2026

Phase II

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…

Novartis Pharma AG

Neoplasms

Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary

18/05/2026

Phase III

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

2025-522007-18-00Relapsed or Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Spain, Norway, Germany, Greece, France, Italy, Netherlands

18/05/2026

Phase III

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

2025-523586-18-00Non-Small Cell Lung Cancer

DrugPembrolizumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia

15/05/2026

Phase I

Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

2025-524052-58-00Healthy Overweight or Obese

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Netherlands

15/05/2026

Phase I

A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167

2026-526096-31-00Chronic Heart Failure

Corteria Pharmaceuticals

Cardiovascular Diseases

Netherlands

13/05/2026

Phase III

A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.

2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…

DrugsObrixtamig·Tocilizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway

13/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-521950-41-00severe uncontrolled asthma

DrugGB-0895

Generate Biomedicines Inc.

Respiratory Tract Diseases

Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia

12/05/2026

Phase III

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

2025-520565-51-00small cell lung cancer

DrugsObrixtamig·Tocilizumab·Atezolizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary

12/05/2026

Phase I

A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

2025-522744-40-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Denmark

11/05/2026

Phase IV

PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

2025-522883-34-00Metastatic cervical cancer

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

11/05/2026

Phase III

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)

2025-524265-24-00Dyslipidemia at High to Very High Cardiovascular Risk

A. Menarini International Licensing S.A.

Hemic and Lymphatic Diseases

Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany

11/05/2026

Phase III

J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

2025-522255-25-00Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neop…

Eli Lilly & Co.

Neoplasms

Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany

11/05/2026

Phase III

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies

2025-522983-33-00Chronic rhinosinusitis with nasal polyps

DrugItepekimab

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland

11/05/2026

Phase III

A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

2025-523134-28-00ABC borderline resectable pancreatic cancer

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

11/05/2026

Phase I/II

LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome

2025-522348-42-00post-COVID syndrome (long COVID)

Amsterdam UMC Stichting

Virus Diseases

Netherlands

07/05/2026

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain

07/05/2026

Phase I

A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

2025-525073-37-00Autosomal Dominant Polycystic Kidney Disease

Glaxosmithkline Research & Development Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

06/05/2026

Phase III

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)

Dompe' Farmaceutici S.p.A.

Eye Diseases

Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France

05/05/2026

Phase II

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

2025-524001-33-00Graves’ Disease

Immunovant Sciences GmbH

Immune System Diseases

Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia

05/05/2026

Phase III

Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)

2026-525163-41-00Inflammatory bowel disease, Fatigue

Radboud universitair medisch centrum Stichting

Digestive System Diseases

Netherlands

04/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)

2024-516993-31-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece

04/05/2026

Phase I

A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS

2026-525517-31-00Not applicable, healthy volunteers

InflaRx GmbH

Not possible to specify

Netherlands

01/05/2026

Phase I

A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.

2026-525575-22-00Psoriasis

Klear Bio Inc.

Skin and Connective Tissue Diseases

Netherlands

30/04/2026

Phase I

A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

2026-525619-15-00Bacterial Infection

Centauri Therapeutics Limited

Bacterial Infections and Mycoses

Netherlands

30/04/2026

Phase I

A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL DOSE OF [14C]-VAFIDEMSTAT IN HEALTHY MALE PARTICIPANTS

2025-524832-20-00Healthy volunteers

Oryzon Genomics S.A.

Not possible to specify

Netherlands

30/04/2026

Phase II

GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery

2024-514089-37-00Patients with pulmonary metastasis from any primary tumour,…

The University Of Birmingham

Neoplasms

Netherlands

30/04/2026

Phase I

Effect of NBI-921355 on corticospinal excitability in healthy participants

2025-524134-26-00Epilepsy

Neurocrine Biosciences Inc.

Nervous System Diseases

Netherlands

29/04/2026

Phase III

An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery

2025-525053-39-00Coronary artery disease

EBI Anti Sepsis B.V.

Cardiovascular Diseases

Belgium, Netherlands

29/04/2026

Phase III

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma

2025-524876-43-00relapsed/refractory multiple myeloma

DrugsElotuzumab·Carfilzomib·Pomalidomide·Bortezomib

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

29/04/2026

Phase III

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

2024-520218-23-00Pulmonary Arterial Hypertension

Inhibikase Therapeutics Inc.

Cardiovascular Diseases

Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania

28/04/2026

Phase II

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

2025-521983-36-00Colorectal cancer (CRC), gastric cancer (GC), pancreatic du…

Blue Earth Diagnostics Ireland Limited

Neoplasms

Netherlands, Italy

28/04/2026

Phase III

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark

28/04/2026

Phase II

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

2025-521154-42-00Sickle Cell Disease

CSL Behring LLC

Hemic and Lymphatic Diseases

Belgium, Netherlands, France, Italy

28/04/2026

Phase IV

MERCURE study: MEthotrexate in ReCurrent dVIN

2025-524373-17-00dVIN caused by Lichen Sclerosus

Amsterdam UMC Stichting

Skin and Connective Tissue Diseases

Netherlands

28/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

2025-522957-20-00Myotonic Dystrophy Type 1

Dyne Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, Italy, Denmark, Germany, Belgium, France

28/04/2026

Phase III

Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity

2023-509176-42-00Obesity and T2D

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria

28/04/2026

Phase II

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis

2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania

27/04/2026

Phase III

Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).

2025-523804-62-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands

27/04/2026

Phase I/II

A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…

DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine

Novartis Pharma AG

Neoplasms

Italy, Spain, Germany, Netherlands, France, Denmark, Czechia

27/04/2026

Phase II

Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)

2026-525211-14-00HIV-1

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Virus Diseases

Netherlands

24/04/2026

Phase I/II

A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.

2025-524438-24-00Type 2 Diabetes

Fractyl Health Inc.

Nutritional and Metabolic Diseases

Netherlands

23/04/2026

Phase III

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardson…

Novartis Pharma AG

Nervous System Diseases

Netherlands, Germany, Spain, Italy, France, Belgium

21/04/2026

Phase II

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

2025-525068-13-00Chronic Kidney Disease

DrugSurvodutide

Universitair Medisch Centrum Groningen

Nutritional and Metabolic Diseases

Germany, Spain, Netherlands

21/04/2026

Phase III

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia

BeOne Medicines I GmbH

Neoplasms

Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden

20/04/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…

CSL Behring LLC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands

20/04/2026

Phase III

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

2024-520014-22-00Locally advanced/metastatic urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

2025-524002-16-00Amyotrophic Lateral Sclerosis

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain

20/04/2026

Phase III

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…

DrugsEnfortumab Vedotin·Pembrolizumab

Eli Lilly & Co.

Neoplasms

Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain

20/04/2026

Phase II

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

DrugVancomycin

MaaT PHARMA

Digestive System Diseases

Netherlands, Italy, France, Spain

17/04/2026

Phase III

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

2025-522748-42-00Ovarian cancer

DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel

Incyte Corp.

Neoplasms

Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium

17/04/2026

Phase III

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

2025-523717-29-00HFpEF or HFmrEF and obesity

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France

17/04/2026

Phase I

A Phase 1 Study of AIR-001 in Adults with AATD.

2025-523558-14-00Alpha-1 Antitrypsin Deficiency

Airna Corp.

Respiratory Tract Diseases

Sweden, Ireland, Spain, Netherlands, Portugal, Germany

17/04/2026

Phase III

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands

17/04/2026

Phase III

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

2025-523096-34-00B-cell Acute Lymphoblastic Leukemia

Prinses Maxima Centrum voor Kinderoncologie B.V.

Hemic and Lymphatic Diseases

Spain, Germany, Netherlands

16/04/2026

Phase II

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer

2025-522162-75-00patients with asymptomatic active brain metastases from sma…

Academisch Ziekenhuis Maastricht

Respiratory Tract Diseases

Netherlands

15/04/2026

Phase I/II

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

2025-522318-21-00Neoplasms, Colorectal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Denmark, Spain, Sweden, Netherlands, France

14/04/2026

Phase II

68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease

2024-511977-31-01giant cell arteritis - polymyalgia rheumatica spectrum dise…

Drug[68Ga]Ga-FAPI-46

Universitair Medisch Centrum Groningen

Cardiovascular Diseases

Netherlands

14/04/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer

DrugPegfilgrastim

Genmab A/S

Neoplasms

Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland

14/04/2026

Phase I/II

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

2024-520052-19-04Malignant Melanoma

Amsterdam UMC Stichting

Therapeutics

Netherlands

13/04/2026

Phase II

A randomized, placebo-controlled trial to assess the efficacy, tolerability, and pharmacokinetics of clemastine in children and adults with Pitt-Hopkins syndrome

2025-524195-29-00Pitt-Hopkins syndrome

Amsterdam UMC Stichting

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

13/04/2026

Phase II

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

2025-523117-28-00Relapsed or Refractory Multiple Myeloma

Glaxosmithkline Research & Development Limited

Neoplasms

France, Germany, Greece, Netherlands, Spain

13/04/2026

Phase IV

Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

2025-524129-42-00Crohn’s disease

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

11/04/2026

Phase I/II

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

2025-522207-15-01Stargardt Disease (STGD1)

Aavantgarde Bio S.r.l.

Eye Diseases

Belgium, Italy, Netherlands, Norway

10/04/2026

Phase II

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

2025-522867-13-00Non Small Cell Lung Cancer

Merus B.V.

Not possible to specify

Spain, Belgium, Netherlands, Poland, Italy, France

09/04/2026

Phase III

An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

2025-522460-33-00Stargardt Disease

DrugTinlarebant

Belite Bio Inc.

Eye Diseases

Netherlands, France, Belgium

07/04/2026

Phase I

A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people

2025-525025-12-00Iron overload from thalassemia, transfusion-dependent myelo…

Pharmacosmos A/S

Hemic and Lymphatic Diseases

Netherlands

07/04/2026

Phase III

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

2025-521108-23-00Chronic Obstructive Pulmonary Disease

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania

07/04/2026

Phase IV

Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial

2025-524440-35-00metastatic castration resistant prostate cancer (mCRPC)

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

07/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy

Rycarma Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, France, Germany

02/04/2026

Phase I

A First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MR-L45 in Healthy Adults

2025-524899-40-00Autosomal Dominant Polycystic Kidney Disease

Mironid Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

01/04/2026

Phase III

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

2025-524229-41-00Triple negative breast cancer

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

01/04/2026

Phase I/II

Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.

2025-522697-37-00Amyotrophic Lateral Sclerosis

VectorY Therapeutics B.V.

Nervous System Diseases

Netherlands, Belgium, Spain

31/03/2026

Phase III

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)

2025-521936-12-00Adults with Type 2 Diabetes and/or Metabolic Syndrome on g…

NewAmsterdam Pharma B.V.

Cardiovascular Diseases

Czechia, Slovakia, Netherlands

31/03/2026

Phase I/II

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)

DrugsRamucirumab·Rilvegostomig

AstraZeneca AB

Neoplasms

Germany, Spain, France, Poland, Belgium, Netherlands, Italy

30/03/2026

Phase I/II

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA)

2024-516976-14-00Metastatic Prostate Cancer

AstraZeneca AB

Male Urogenital Diseases

Netherlands, Spain

30/03/2026

Phase III

Intranasal insulin for the prevention of delirium in ICU patients undergoing elective cardiac surgery: a randomized, double blind, placebo controlled pilot trial (INSPIRE)

2025-524680-21-00Delirium

Radboud universitair medisch centrum Stichting

Nervous System Diseases

Netherlands

30/03/2026

Phase IV

Healing Diabetic Foot Ulcers with Semaglutide

2025-524738-24-00Diabetic foot ulcer

Radboud universitair medisch centrum Stichting

Cardiovascular Diseases

Netherlands

30/03/2026

Phase I

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia

2025-522617-39-00Refractory hyperlipidemia

Verve Therapeutics Inc.

Cardiovascular Diseases

Netherlands

30/03/2026

Phase II

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

2024-511510-20-00craniopharyngioma

DrugTovorafenib

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands, France, Germany

25/03/2026

Phase III

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

2025-523085-24-00Biliary Tract Cancer

AstraZeneca AB

Neoplasms

Germany, Poland, Italy, Belgium, France, Netherlands, Spain

23/03/2026

Phase II

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects in Patients with Heart Failure or Cardiovascular Disease and Chronic Kidney Disease (COMPARE-VS)

2025-523743-35-00Heart failure, cardiovascular disease, chronic kidney disea…

Universitair Medisch Centrum Groningen

Cardiovascular Diseases

Netherlands

23/03/2026

Phase III

C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

2025-523521-18-00Metastatic Colorectal Cancer

DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin

Pfizer Inc.

Neoplasms

Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark

23/03/2026

Phase I/II

FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial

2025-520814-78-00Diffuse Midline Glioma, H3K27-altered

DrugTemozolomide

Universitair Medisch Centrum Utrecht

Nervous System Diseases

Netherlands

23/03/2026

Phase II

A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder

2025-524133-33-00Opioid use disorder

Cessation Therapeutics Inc.

Anesthesia and Analgesia

Netherlands

20/03/2026

Phase II

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)

2025-523033-26-00Patients with EGFR-mutated metastatic NSCLC, without CNS me…

DrugsFebuxostat·Osimertinib

Academisch Ziekenhuis Maastricht

Respiratory Tract Diseases

Netherlands

19/03/2026

Phase II

J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

2025-522338-30-00Ulcerative Colitis

Eli Lilly & Co.

Digestive System Diseases

Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria

18/03/2026

Phase I/II

Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 in combination with anti-PD1 treatment in patients with melanoma

2024-516545-39-01unresectable stage III – IV melanoma

DrugIpilimumab

Stichting Amsterdam UMC

Neoplasms

Netherlands

18/03/2026

Phase III

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

2024-513445-37-00previously untreated RT, irrespective of risk factors and d…

DrugsEpcoritamab·Pirtobrutinib·Prednisolone·Vincristine

University Of Cologne

Neoplasms

Austria, Germany, Denmark, Ireland, Netherlands, Italy

18/03/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency

2025-522051-26-00Acquired Angioedema due to C1 Inhibitor Deficiency

DrugDeucrictibant

Pharvaris Netherlands B.V.

Immune System Diseases

Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria

17/03/2026

Phase IV

Cholesterol lowering with atorvastatine for the prevention of gallstones following bariatric surgery (CHOLSTONE): an investigator- blinded randomised controlled trial

2025-524191-38-00Gallstones (chole(cysto)lithiasis) following bariatric surg…

DrugAtorvastatin

Spaarne Gasthuis Stichting

Nutritional and Metabolic Diseases

Netherlands

17/03/2026

Phase III

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

2025-522191-86-00Focal segmental glomerulosclerosis

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Female Urogenital Diseases and Pregnancy Complications

Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France

17/03/2026

Phase II

SHIELD – Swift Hydrocortisone Intervention after trauma exposure

2025-523350-13-02Posttraumatic Stress Disorder (PTSD)

Amsterdam UMC Stichting

Mental Disorders

Netherlands

17/03/2026

Phase III

AchilleS tendinoPathy treated with cortIcosteRoid injEctions.

2025-524057-13-00Achilles tendinopathy

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Musculoskeletal Diseases

Netherlands

16/03/2026

Phase III

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)

2025-522878-36-00Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics Inc.

Skin and Connective Tissue Diseases

Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland

16/03/2026

Phase II

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

2024-511656-41-00Duchenne Muscular Dystrophy

Biomarin Pharmaceutical Inc.

Musculoskeletal Diseases

Spain, Italy, Netherlands

16/03/2026

Phase I

Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer: a phase I study

2025-522864-34-00Gastric cancer

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

16/03/2026

Phase II

Comparison of esketamine mouthwash versus intravenous administration for the treatment of chemotherapy/radiotherapy-induced mucositis

2025-522545-22-00Oral mucositis

DrugEsketamine

Amsterdam UMC Stichting

Anesthesia and Analgesia

Netherlands

13/03/2026

Phase IV

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)

2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis

DrugUpadacitinib

Care Arthritis Ltd.

Eye Diseases

Spain, Poland, Netherlands, France, Bulgaria, Germany

13/03/2026

Phase II

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)

2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Nervous System Diseases

Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands

12/03/2026

Phase I

Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease

CRISPR Therapeutics AG

Hemic and Lymphatic Diseases

Spain, Germany, France, Denmark, Italy, Netherlands

12/03/2026

Phase I

A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

2025-524856-73-00Not Applicable

F. Hoffmann-La Roche AG

Population Characteristics

Netherlands

11/03/2026

Phase II

INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS

2024-515009-24-00High grade malignant brain neoplasm

Clinica Universidad De Navarra

Nervous System Diseases

Netherlands, Spain

11/03/2026

Phase II

Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study

2024-519884-16-00Sjögren's syndrome

DrugObinutuzumab

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

11/03/2026

Phase III

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

2025-523224-45-00Untreated, Unresectable or Metastatic Colorectal Cancer

DrugsCalcium folinate·Fluorouracil·Irinotecan·Capecitabine

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria

10/03/2026

Phase I/II

HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia

2025-522295-91-00relapsed or refractory Waldenstrom’s macroglobulinemia

DrugEpcoritamab

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasms

Denmark, Belgium, Netherlands

10/03/2026

Phase I/II

Late immunity following single immunization with GA2 sporozoites (GACHA)

2025-524045-27-00Falciparum malaria

Leids Universitair Medisch Centrum (LUMC)

Parasitic Diseases

Netherlands

09/03/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

2025-522831-33-00Hidradenitis Suppurativa

DrugZasocitinib

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

France, Poland, Netherlands, Germany

06/03/2026

Phase I

A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

2025-524693-42-00Stable Coronary Artery Disease (CAD)

F. Hoffmann-La Roche AG

Cardiovascular Diseases

Netherlands

06/03/2026

Phase I

A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants

2025-524172-29-00Healthy volunteers

Novartis Pharma AG

Not possible to specify

Netherlands

06/03/2026

Phase II

A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis

2025-522511-42-00Crohn's disease, Colitis Ulcerative

DrugBalinatunfib

Sanofi-Aventis Recherche & Developpement

Digestive System Diseases

Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary

06/03/2026

Phase I

Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321

2025-524053-14-00Graves Disease

Lycia Therapeutics Inc.

Immune System Diseases

Netherlands

06/03/2026

Phase III

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

2025-521884-12-00First line triple-negative breast cancer (TNBC)

DrugsEribulin·Gemcitabine·Paclitaxel·Carboplatin

BioNTech SE

Neoplasms

Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain

04/03/2026

Phase III

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis

2025-521546-23-00Secondary progressive multiple sclerosis

Novartis Pharma AG

Nervous System Diseases

Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway

03/03/2026

Phase III

A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)

2025-522383-33-00Pulmonary fibrosis, Interstitial lung diseases, Familial pu…

Boehringer Ingelheim International GmbH

Respiratory Tract Diseases

Belgium, Spain, Netherlands, Italy, Germany, France

03/03/2026

Phase II

Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study

2025-522060-32-00STEMI (ST elevated Myocardial Infarction)

DrugAdenosine

CorFlow Therapeutics AG, CorFlow Therapeutics AG

Cardiovascular Diseases

Netherlands, Spain, France

02/03/2026

Phase II

Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases

2025-522834-30-01Systemic sclerosis (SSc), Idiopathic pulmonary fibrosis (IP…

Amsterdam UMC Stichting

Skin and Connective Tissue Diseases

Netherlands

02/03/2026

Phase III

A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients with Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

2024-519384-18-00Colorectal, Gastric, Ovarian or Pancreatic Cancer

GE Healthcare Limited

Diagnosis

Sweden, Netherlands

25/02/2026

Phase I

A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic peripheral neuropathy

2025-524258-32-00Diabetic Peripheral Neuropathy (DPN)

Tenvie Therapeutics Inc.

Musculoskeletal and Neural Physiological Phenomena

Netherlands

24/02/2026

Phase III

J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Dise…

Eli Lilly & Co.

Cardiovascular Diseases

Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium

24/02/2026

Phase II

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …

Merck Sharp & Dohme LLC

Neoplasms

Italy, Poland, Spain, Finland, Netherlands, Greece

24/02/2026

Phase III

A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease

2025-521037-86-00Immune system diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia

24/02/2026

Phase III

A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease

2025-521036-11-00Immune system disseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France

24/02/2026

Phase III

INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS

2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopen…

Incyte Corp.

Hemic and Lymphatic Diseases

Netherlands, Italy, Spain, France

23/02/2026

Phase I/II

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

2022-502911-12-00Propionic Acidemia

Moderna Inc.

Nutritional and Metabolic Diseases

Spain, Netherlands, France

23/02/2026

Phase I/II

A Phase 1 Study of Fentanyl Vaccine

2025-524277-16-00Opioid induced respiratory depression

ARMR Sciences Inc.

Environment and Public Health

Netherlands

23/02/2026

Phase III

A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients

2025-521521-33-00Kidney transplant rejection

DrugsFrexalimab·Tacrolimus

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands

23/02/2026

Phase IV

CANIDIAP; CANagliflozin In DIAlysis Patients

2025-522742-46-00Chronic Kidney disease

DrugCanagliflozin

Universitair Medisch Centrum Groningen

Not possible to specify

Netherlands

23/02/2026

Phase II

Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.

2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…

Argenx

Immune System Diseases

Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium

18/02/2026

Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

2025-523515-11-00Early Alzheimer's Disease

Denali Therapeutics Inc.

Nervous System Diseases

Netherlands

18/02/2026

Phase III

J2A-MC-GZPR: A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial

2025-523283-21-00Peripheral Arterial Disease

Eli Lilly & Co.

Cardiovascular Diseases

Slovakia, Poland, France, Netherlands

17/02/2026

Phase III

A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)

2025-522873-12-00ER+, HER2- Advanced Breast Cancer

Olema Pharmaceuticals Inc.

Neoplasms

Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands

17/02/2026

Phase II

Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

2025-521390-14-00Acute Myeloid Leukemia

DrugsRevumenib·Cytarabine·Fludarabine

Pediatric Research International GmbH

Neoplasms

Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria

16/02/2026

Phase III

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia

2025-523533-25-00Cancer-associated Cachexia

CatalYm GmbH

Nutritional and Metabolic Diseases

France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands

13/02/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the effects of SUL-238 on High Energy Phosphates with Magnetic Resonance Spectroscopy (31P-MRS) in patients with Early, untreated Parkinson’s Disease (“SHEPHERD” STUDY)

2025-524674-42-00Parkinson’s Disease

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.

Nervous System Diseases

Netherlands

13/02/2026

Phase I/II

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posi…

Amgen Inc.

Neoplasms

France, Netherlands, Italy

13/02/2026

Phase II

Accuracy for Imaging Cardiac Sarcoidosis with 68Ga-Pentixafor Positron Emission Tomography/Computed Tomography (68Ga-Pentixafor PET/CT): ASPECT study

2025-523646-27-00Cardiac Sarcoidosis

Drug[68Ga]Ga-PentixaFor

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Diagnosis

Netherlands

12/02/2026

Phase III

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).

2025-523275-27-00Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyri…

Disc Medicine Inc.

Nutritional and Metabolic Diseases

Italy, France, Ireland, Belgium, Sweden, Germany, Netherlands, Norway, Spain

12/02/2026

Phase I

A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

2025-524210-28-00Not Applicable

F. Hoffmann-La Roche AG

Population Characteristics

Netherlands

11/02/2026

Phase I

A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

2025-522582-30-00Alzheimer’s Disease

Alnylam Pharmaceuticals Inc.

Nervous System Diseases

Spain, Netherlands

10/02/2026

Phase II

A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.

2025-523231-19-00Cutaneous Squamous Cell Carcinoma

Philogen S.p.A.

Neoplasms

Italy, Germany, Greece, Spain, Austria, France, Netherlands

10/02/2026

Phase II

A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.

2025-523229-16-00locally advanced basal cell carcinoma patients

Philogen S.p.A.

Skin and Connective Tissue Diseases

Greece, Italy, Germany, Spain, Netherlands

10/02/2026

Phase III

An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma

2024-519504-27-00Relapsed Refractory Multiple Myeloma

DrugsDiphenhydramine hydrochloride·Linvoseltamab·Paracetamol·Velcade

Regeneron Pharmaceuticals Inc.

Neoplasms

Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France

10/02/2026

Phase III

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)

2025-520923-25-00Juvenile Idiopathic Arthritis

Duke Clinical Research Institute

Immune System Diseases

Italy, Netherlands, Germany

10/02/2026

Phase III

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

2025-520805-10-00Chronic inflammatory demyelinating polyneuropathy (CIDP)

DrugEmpasiprubart

Argenx

Nervous System Diseases

Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania

10/02/2026

Phase III

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination with Osimertinib, Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

2025-521124-29-00Non-Small Cell Lung Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Italy, Spain, Poland, Netherlands, Germany, Belgium, Austria, France

09/02/2026

Phase III

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE

2025-521142-22-00Hereditary Angioedema

Astria Therapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria

09/02/2026

Phase III

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis

2025-521038-27-00Immune system diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway

09/02/2026

Phase III

2025-521035-37-00Immune system diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland

09/02/2026

Phase I

A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers

2025-524527-46-00Ocular inflammatory conditions

Dompe' Farmaceutici S.p.A.

Eye Diseases

Netherlands

09/02/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

2025-522229-37-00Gastrointestinal Neoplasms

Glaxosmithkline Research & Development Limited

Neoplasms

France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany

06/02/2026

Phase I

A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

2025-523108-59-00Severe infections caused by Gram-negative bacteria

Basilea Pharmaceutica International AG Allschwil

Bacterial Infections and Mycoses

Netherlands

06/02/2026

Phase I

A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers.

2025-523328-31-00Inflammatory diseases

Almirall S.A.

Immune System Diseases

Netherlands

06/02/2026

Phase III

Multicentre, open-label, randomised, controlled, parallel-arms, phase III, clinical trial of Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer: MEND-IT II

2025-523692-39-00locally advanced rectal cancer

Catharina Ziekenhuis Stichting

Neoplasms

Netherlands

04/02/2026

Phase II

Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study

2025-523032-39-00Non-small cell lung cancer

Drug[68Ga]Ga-FAPI-46

Academisch Ziekenhuis Maastricht

Diagnosis

Netherlands

03/02/2026

Phase I/II

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D

2025-522253-19-00Urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, France, Spain

03/02/2026

Phase III

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

2025-522960-34-00Hypertension, Established cardiovascular disease, High card…

Alnylam Pharmaceuticals Inc.

Cardiovascular Diseases

Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria

03/02/2026

Phase III

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).

2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.

Kardigan Inc.

Cardiovascular Diseases

Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands

30/01/2026

Phase I

PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

2025-523781-25-00metastatic solid cancer, muscle invasive bladder cancer, lo…

CimCure B.V.

Neoplasms

Netherlands

29/01/2026

Phase III

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)

2025-522387-32-00Uveal Melanoma

Ideaya Biosciences Inc.

Eye Diseases

France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany

29/01/2026

Phase IV

The efficacy of pipamperone and aripiprazole on behaviors that challenge in people with intellectual disabilities: A series of N-of-1 cross-over trials

2024-519833-51-00Behaviors that challenge

Stichting GGZ Drenthe

Behavioral Disciplines and Activities

Netherlands

28/01/2026

Phase III

An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

2025-522792-29-00Alpha-1 Antitrypsin Deficiency

DrugIVIG

Grifols Therapeutics LLC

Respiratory Tract Diseases

Poland, Denmark, Netherlands, Ireland, Sweden, Spain, Portugal, Germany, France

27/01/2026

Phase III

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

2025-522674-36-00Metabolic Dysfunction-Associated Steatotic Liver Disease

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium

27/01/2026

Phase III

Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)

2025-522404-24-01Lung Cancer

DrugNelarabine

Amsterdam UMC Stichting

Neoplasms

Netherlands

27/01/2026

Phase IV

Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy

2024-518822-33-01Cerebral Palsy

DrugBaclofen

UZ Leuven

Nervous System Diseases

Netherlands, Belgium

27/01/2026

Phase III

An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia

2024-519068-42-00Heterozygous Familial Hypercholesterolemia in pediatric p…

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland

26/01/2026

Phase III

Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)

2025-521792-31-01Homozygous Familial Hypercholesterolemia (HoFH)

DrugZodasiran

Arrowhead Pharmaceuticals Inc.

Cardiovascular Diseases

Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy

23/01/2026

Phase I

A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

2025-524310-28-00Epilepsy, amotrophic lateral sclerosis, neuropathy

Quralis Corp.

Nervous System Diseases

Netherlands

23/01/2026

Phase I/II

A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis

2025-522039-33-00Amyotrophic Lateral Sclerosis

Leal Therapeutics Inc.

Nervous System Diseases

Sweden, Italy, Germany, Netherlands

23/01/2026

Phase II

J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma

2025-522640-41-00Asthma

Eli Lilly & Co.

Respiratory Tract Diseases

Germany, Netherlands, France, Poland

21/01/2026

Phase I/II

A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME

2025-521973-16-00Netherton Syndrome

Biocryst Pharmaceuticals Inc.

Skin and Connective Tissue Diseases

France, Netherlands, Germany

20/01/2026

Phase III

Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

2025-521284-12-00Non-small cell lung cancer

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark

19/01/2026

Phase III

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

2025-521908-22-00EGFR-mutated Non-small Cell Lung Cancer

DrugsPegfilgrastim·Iza-bren·Pemetrexed·Cisplatin

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Poland, Germany, Italy, Norway, Netherlands, Belgium, Romania, France, Greece, Spain

19/01/2026

Phase III

Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation

2025-522027-95-00oral squamous cell carcinoma

DrugCetuximab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

19/01/2026

Phase III

HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study

2025-522767-15-00Acute Myeloid Leukemia

DrugBleximenib

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasms

Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland

15/01/2026

Phase III

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2025-521917-24-00Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous…

Janssen Cilag International

Neoplasms

Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium

14/01/2026

Phase III

The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green

2025-523898-42-00Histologically confirmed solid malignancy (e.g., head and n…

DrugIndocyanine Green

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

13/01/2026

Phase I

A Single-Center, Double-Blind, Randomized, Placebo Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of ACI-19764 in Healthy Participants and in Participants with Cardiovascular Risk Factors

2025-523885-25-00Healthy Volunteers, Participants with diabetes and/or overw…

AC Immune S.A.

Nutritional and Metabolic Diseases

Netherlands

13/01/2026

Phase III

A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors

2025-521043-20-00Neuroendocrine tumors

Exelixis Inc.

Neoplasms

France, Poland, Netherlands, Belgium, Germany, Spain, Italy, Austria

09/01/2026

Phase I/II

Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)

2025-521420-30-00Inflammatory Bowel Disease (IBD)

Universitair Medisch Centrum Groningen

Digestive System Diseases

Netherlands

06/01/2026

Phase II

Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson’s Disease

2025-521819-39-00Parkinson's disease

DrugTadalafil

Amsterdam UMC Stichting

Nervous System Diseases

Netherlands

05/01/2026

Phase I

A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy

2025-523469-79-00Spinal and Bulbar Muscular Atrophy

Arvinas Operations Inc.

Nervous System Diseases

Netherlands

24/12/2025

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease

2025-522683-32-00Early-Stage Parkinson’s Disease (PD)

F. Hoffmann-La Roche AG

Nervous System Diseases

France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy

23/12/2025

Phase II

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

2025-522333-61-00Hidradenitis suppurativa

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece

22/12/2025

Phase III

A Phase 3, multicentre, randomised (1:1), parallel-group, active-controlled, central reader colonoscopist-blind study to evaluate the bowel cleansing efficacy, safety, tolerability, palatability, and acceptability of PLENVU® as compared to sodium picosulfate in paediatric participants from 1 to < 18 years of age in preparation for colonoscopy (CLARITY)

2025-522046-42-00Colonic disease

Norgine Limited

Digestive System Diseases

Poland, Netherlands, Hungary, Spain, Italy, Belgium, Germany, Croatia, Portugal

22/12/2025

Phase I

A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants

2025-523430-14-00Psoriasis

Janssen Cilag International

Immune System Diseases

Netherlands

22/12/2025

Phase III

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

2025-521117-88-00Cardiovascular Disease

Amgen Inc.

Cardiovascular Diseases

France, Denmark, Germany, Spain, Italy, Netherlands

22/12/2025

Phase III

A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer

2024-515765-34-00English First-line extensive-stage small-cell lung cancer (…

BioNTech SE

Neoplasms

Poland, Spain, France, Italy, Germany, Romania, Netherlands

22/12/2025

Phase I/II

Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…

DrugMK-3120

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France

22/12/2025

Phase III

C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Pfizer Inc.

Not possible to specify

Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece

22/12/2025

Phase I/II

SPRAYDYE-Trial - A phase I/II study to assess the efficacy, safety and tolerability of topically applied 6qc-ICG, a cathepsin-activatable fluorescent probe, for real-time intraoperative resection margin assessment in breast conserving surgery

2025-523166-24-00Breast cancer

Leids Universitair Medisch Centrum (LUMC)

Neoplasms

Netherlands

22/12/2025

Phase III

A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.

2025-522361-30-00Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G va…

DrugSonlicromanol

Khondrion B.V.

Nervous System Diseases

Italy, Germany, France, Netherlands, Denmark

19/12/2025

Phase I

A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.

2025-523791-24-00Multiple sclerosis

Immunic AG

Nervous System Diseases

Netherlands

17/12/2025

Phase I/II

A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)

2023-507597-40-00B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands

16/12/2025

Phase IV

Assessing residual inflammation and macrophage presence in lupus nephritis after 3 months of intensified treatment with prednisolone, mycofenolate mofetil and voclosporin as compared to mycofenolate mofetil and prednisolone: an open label randomized controlled trial (MAPLE study)

2025-522187-32-01Lupus Nephritis

Amsterdam UMC Stichting

Immune System Diseases

Netherlands

15/12/2025

Phase IV

The effect of transdermal 17-β-estradiol/progesterone supplementation on glucose regulation in peri- and postmenopausal women with type 1 and type 2 diabetes

2025-523214-83-00Diabetes Mellitus, (peri) Menopause

Amsterdam UMC Stichting

Hormonal diseases

Netherlands

15/12/2025

Phase III

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease

2025-521113-13-00Early Parkinson’s Disease

Biohaven Therapeutics Ltd.

Nervous System Diseases

Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal

15/12/2025

Phase I

A study in healthy men and women to test how BI 3000202 is taken up and processed by the body

2023-510345-21-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Netherlands

12/12/2025

Phase III

IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator-initiated multicentre randomised phase 3 trial (M24IMS)

2025-522500-24-00Head and Neck squamous cell carcinoma

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

12/12/2025

Phase III

A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

2025-521661-27-00Primary Membranous Nephropathy

Vertex Pharmaceuticals Inc.

Immune System Diseases

Hungary, Ireland, Czechia, Italy, Spain, Germany, Netherlands

12/12/2025

Phase I

A study in healthy men to test how BI 1584862 is processed in the body

2025-522311-41-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Netherlands

10/12/2025

Phase III

AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

2025-520982-39-00Philadelphia Chromosome Positive or ABL-class Philadelphia …

Universita Degli Studi Di Milano Bicocca

Neoplasms

France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands

09/12/2025

Phase III

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension

2024-519578-38-00Classic congenital adrenal hyperplasia

Crinetics Pharmaceuticals Inc.

Hormonal diseases

Italy, Germany, France, Belgium, Netherlands, Poland

09/12/2025

Phase I

Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib

2025-523340-12-00Glioma

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

09/12/2025

Phase III

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).

2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…

Novo Nordisk A/S

Cardiovascular Diseases

Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia

09/12/2025

Phase III

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

2023-509392-17-00Relapsed Acute Lymphoblastic Leukemia (ALL)

DrugsIdarubicin·Inotuzumab Ozogamicin·Pegaspargase·Mercaptopurine

Charite Universitaetsmedizin Berlin KöR

Hemic and Lymphatic Diseases

Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Slovenia

09/12/2025

Phase I

PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors.

2025-521180-13-00Diffuse Midline Glioma (DMG), and Other Recurrent Primary M…

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands

08/12/2025

Phase III

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

2024-512804-20-00Metastatic Colorectal Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Germany, Poland, France, Italy, Netherlands, Spain

08/12/2025

Phase II

A single-center, randomized, double blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis

2025-522922-11-00Progressive multiple sclerosis (MS)

Idorsia Pharmaceuticals Ltd.

Nervous System Diseases

Netherlands

08/12/2025

Phase III

A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)

2024-512486-14-00Short Bowel Syndrome

DrugGlepaglutide

Zealand Pharma A/S

Digestive System Diseases

Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia

04/12/2025

Phase I/II

Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Patients with Hormone Sensitive Prostate Cancer. - The DARO-flare Trial -

2025-520482-52-03Prostate cancer

DrugDarolutamide

Amsterdam UMC Stichting

Diagnosis

Netherlands

04/12/2025

Phase I/II

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

2025-522659-24-00Ovarian carcinoma

DrugAldesleukin

Leids Universitair Medisch Centrum (LUMC)

Neoplasms

Netherlands

03/12/2025

Phase IV

Rapid sequence emergence of general Anaesthesia

2024-516415-24-03General anesthesia

DrugsFlumazenil·Rocuronium·Sugammadex·Remimazolam

Stichting Radboud universitair medisch centrum

Anesthesia and Analgesia

Netherlands

02/12/2025

Phase II

SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial

2025-521866-92-01long COVID

Amsterdam UMC Stichting

Virus Diseases

Netherlands

02/12/2025

Phase III

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia

2024-519579-24-00Classic Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals Inc.

Hormonal diseases

Sweden, Austria, Poland, Netherlands, Italy, France, Germany

02/12/2025

Phase I

First-in-Human Study of RO7812653

2025-522101-37-00Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitiv…

F. Hoffmann-La Roche AG

Nervous System Diseases

Sweden, Poland, Spain, Netherlands

02/12/2025

Phase III

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

2025-521382-27-00Moderately to Severely Active Crohn's Disease

Janssen Cilag International

Immune System Diseases

Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland

01/12/2025

Phase III

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

2025-521381-10-00Moderately to Severely Active Ulcerative Colitis

Janssen Cilag International

Digestive System Diseases

Netherlands, Romania, Italy, Spain, Sweden, Czechia, Greece, Hungary, France, Portugal, Belgium, Germany, Poland

01/12/2025

Phase III

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)

2025-521970-33-00Pulmonary Arterial Hypertension (PAH)

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands

01/12/2025

Phase I

A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin

2025-521921-34-00Overweight or Obese (otherwise healthy)

Genentech Inc.

Nutritional and Metabolic Diseases

Netherlands

01/12/2025

Phase III

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

2024-520097-36-00Chronic inflammatory demyelinating polyneuropathy (CIDP)

DrugEmpasiprubart

Argenx

Nervous System Diseases

Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany

01/12/2025

Phase II

A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.

2025-522146-40-00Late-onset Pompe disease.

Shionogi B.V.

Nutritional and Metabolic Diseases

Belgium, Germany, Denmark, France, Italy, Spain, Netherlands

01/12/2025

Phase II

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)

DrugVX-407

Vertex Pharmaceuticals Inc.

Genetic Phenomena

France, Germany, Italy, Belgium, Spain, Netherlands

28/11/2025

Phase III

A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

2025-522598-12-00Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden

28/11/2025

Phase II

BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED.

2023-508116-32-00Antibody-mediated rejection of renal grafts, High HLA-immun…

Academisch Ziekenhuis Leiden

Immune System Phenomena

Netherlands

27/11/2025

Phase III

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

2024-514500-14-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …

Merck Sharp & Dohme LLC

Neoplasms

Germany, Italy, France, Poland, Spain, Hungary, Romania, Greece, Austria, Netherlands, Belgium

27/11/2025

Phase I

A Study Investigating the Safety and Absorption of Different Administration forms of RO7795074, a New Compound that may Potentially be Used in the Treatment of Type 1 Diabetes

2025-521888-13-00Overweight or Obese (otherwise healthy)

Genentech Inc.

Nutritional and Metabolic Diseases

Netherlands

26/11/2025

Phase II

A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative

2023-506982-73-00high risk or poor response after chemoradiation and brachyt…

DrugsLenvatinib·Pembrolizumab

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Female Urogenital Diseases and Pregnancy Complications

Netherlands

25/11/2025

Phase III

Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

2024-515023-11-00Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear …

DrugsCasdatifan·Cabozantinib

Arcus Biosciences Inc.

Neoplasms

Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary

24/11/2025

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

2024-520418-22-00Chronic Obstructive Pulmonary Disease

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal

24/11/2025

Phase IV

Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial

2025-521316-19-00Urolithiasis

Leids Universitair Medisch Centrum (LUMC)

Anesthesia and Analgesia

Netherlands

21/11/2025

Phase III

Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial

2024-516898-72-00Perihilar cholangiocarcinoma, distal cholangiocarcinoma

Stichting Amsterdam UMC

Neoplasms

Netherlands

21/11/2025

Phase I/II

An open-label, non-randomized, extension study to further investigate the long-term efficacy, safety, and tolerability of Guanabenz in patients with early childhood onset vanishing white matter (VWM)

2024-518834-95-02Vanishing white matter

Amsterdam UMC Stichting

Nervous System Diseases

Netherlands

21/11/2025

Phase II

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM

2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy

Imbria Pharmaceuticals Inc.

Cardiovascular Diseases

Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland

20/11/2025

Phase III

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

2025-522860-34-00Small lymphocytic lymphoma (SLL), Chronic lymphocytic leuke…

BeOne Medicines AG

Neoplasms

Sweden, Belgium, Spain, Germany, Austria, Netherlands, Italy, Romania, Poland, France

18/11/2025

Phase III

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer

2025-520927-26-00Metastatic Castration-resistant Prostate Cancer (mCRPC)

Janssen Cilag International

Neoplasms

France, Belgium, Spain, Poland, Italy, Netherlands, Germany

18/11/2025

Phase III

C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS

2022-503070-36-00Group B streptococcus (GBS) disease

Pfizer Inc.

Bacterial Infections and Mycoses

Finland, Netherlands, Spain

18/11/2025

Phase II

A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

2025-520518-79-00Atrial Fibrillation

Novartis Pharma AG

Cardiovascular Diseases

Netherlands, Germany

17/11/2025

Phase III

sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT

2024-519540-32-00post COVID

Amsterdam UMC Stichting

Virus Diseases

Netherlands

17/11/2025

Phase III

C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)

Pfizer Inc.

Neoplasms

Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria

17/11/2025

Phase III

NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial

2025-520979-13-00Patients with HR+ HER2- early breast cancer at intermediate…

Unicancer

Neoplasms

Germany, Spain, Netherlands, France, Italy

17/11/2025

Phase I

Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS

2025-523872-22-00Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)

Nrg Therapeutics Limited

Nervous System Diseases

Netherlands

17/11/2025

Phase III

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

2024-518777-34-00B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

DrugsDoxorubicin·Paclitaxel

AstraZeneca AB

Neoplasms

Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia

17/11/2025

Phase III

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.

2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…

DrugsTreosulfan·Thiotepa·Busulfan·Blinatumomab

Ospedale Pediatrico Bambino Gesu

Hemic and Lymphatic Diseases

Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia

17/11/2025

Phase I

First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

2025-521431-37-00Parkinson's disease

Regeneron Pharmaceuticals Inc.

Nervous System Diseases

Netherlands, Belgium

17/11/2025

Phase I

The effect of SYX-5219 on an immune response in the skin.

2025-522217-27-00Atopic dermatitis (AD)

Sitryx Therapeutics Limited

Skin and Connective Tissue Diseases

Netherlands

14/11/2025

Phase I

A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the Single-Dose Pharmacokinetics of ARV-102 in Healthy Participants.

2025-523370-16-00Parkinsonian syndromes

Arvinas Operations Inc.

Nervous System Diseases

Netherlands

14/11/2025

Phase I

A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

2025-522045-21-00Solid tumours, Melanoma

Boehringer Ingelheim International GmbH

Neoplasms

Belgium, Netherlands

14/11/2025

Phase III

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)

2024-513586-39-00Prostate Cancer

AstraZeneca AB

Male Urogenital Diseases

Austria, Sweden, Spain, France, Netherlands, Germany, Belgium, Finland, Hungary, Poland, Italy

12/11/2025

Phase I/II

A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

2025-521441-24-00Advanced or Metastatic Solid Tumors

Alentis Therapeutics AG

Neoplasms

Spain, France, Netherlands, Italy

12/11/2025

Phase II

A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization

2025-521325-33-00Chronic angina and left ventricular dysfunction due to coro…

Xylocor Therapeutics Inc.

Cardiovascular Diseases

Netherlands, Germany, Hungary, Poland

11/11/2025

Phase II

RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

2024-510926-19-00Myelofibrosis

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

11/11/2025

Phase III

A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

2025-523083-21-00PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gr…

Relay Therapeutics Inc.

Neoplasms

Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania

11/11/2025

Phase II

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

2025-521242-26-00Moderately to Severely Active Ulcerative Colitis

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia

10/11/2025

Phase II

SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions

2025-522962-58-00Renal cell carcinom

Leids Universitair Medisch Centrum (LUMC)

Neoplasms

Netherlands

10/11/2025

Phase I

A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

2025-522766-78-00Not Applicable

F. Hoffmann-La Roche AG

Population Characteristics

Netherlands

07/11/2025

Phase I

A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants

2025-522320-27-00Not applicable - healthy volunteer trial

Viatris Innovation GmbH

Not possible to specify

Netherlands

07/11/2025

Phase III

A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY Kids)

2024-512577-27-00Chronic kidney disease in paediatric patients

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Spain, Germany, Portugal, Netherlands, Belgium, Poland, Italy, France, Sweden, Hungary

06/11/2025

Phase III

STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease

2025-521276-59-00Autosomal dominant polycystic kidney disease (ADPKD)

University Of Cologne

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands, Austria, Spain, Germany

06/11/2025

Phase II

Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety (EXACT-2 Trial)

2024-514874-36-01Refractory angina due to obstructive coronary artery disease

Xylocor Therapeutics Inc.

Cardiovascular Diseases

Belgium, Poland, Hungary, Netherlands, Germany

04/11/2025

Phase III

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia

2025-521692-31-00Chronic Primary Immune Thrombocytopenia

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

Bulgaria, Spain, Netherlands, Italy, Poland, Greece, Germany, France, Czechia, Croatia, Norway, Sweden

04/11/2025

Phase III

EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)

2024-519404-27-00IDH-mutant grade 2 or 3 astrocytoma

Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Neoplasms

Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium

04/11/2025

Phase III

Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial

2025-522194-11-00Respiratory Syncytial Virus (RSV)

Fondazione Penta Ets

Respiratory Tract Diseases

Belgium, Netherlands

04/11/2025

Phase III

A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

2024-518008-33-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…

F. Hoffmann-La Roche AG

Nervous System Diseases

Poland, France, Germany, Netherlands, Spain, Italy, Denmark

04/11/2025

Phase I/II

(22931) A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.

2025-520623-24-00MTAP-deleted Solid Tumors

Bayer AG

Neoplasms

Belgium, Sweden, Denmark, Italy, Spain, Netherlands, Czechia

04/11/2025

Phase III

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

2025-521012-18-00Facioscapulohumeral Muscular Dystrophy (FSHD)

Avidity Biosciences Inc.

Musculoskeletal Diseases

Italy, France, Germany, Spain, Denmark, Netherlands

04/11/2025

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

2024-519493-39-00High-risk Non-muscle-invasive Bladder Cancer with Susceptib…

Janssen Cilag International

Neoplasms

France, Germany, Spain, Netherlands, Italy, Belgium, Greece

03/11/2025

Phase I

A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene

2025-522002-20-00PLN R14del Dilated Cardiomyopathy

AstraZeneca AB

Cardiovascular Diseases

Netherlands

03/11/2025

Phase III

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria

2024-519554-37-00Phenylketonuria

Otsuka Pharmaceutical Development & Commercialization Inc.

Nervous System Diseases

Czechia, Italy, Spain, Netherlands, Poland, France, Germany

03/11/2025

Phase III

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

2025-520555-89-00Metastatic castration-resistant prostate cancer (mCRPC)

Amgen Inc.

Neoplasms

Austria, Netherlands, Portugal, Spain, Belgium, Greece, France, Italy, Germany

03/11/2025

Phase II

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

2025-523009-14-00Bronchiectasis with chronic pseudomonas aeruginosa coloniza…

AstraZeneca AB

Respiratory Tract Diseases

Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany

31/10/2025

Phase I

A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

2025-522930-29-00Incomplete Response - Major Depressive Disorder (IR-MDD)

Otsuka Pharmaceutical Development & Commercialization Inc.

Mental Disorders

Netherlands

31/10/2025

Phase I/II

The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy

2025-521163-12-01Graves' Orbitopathy

Drug[68Ga]Ga-FAPI-46

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Immune System Diseases

Netherlands

30/10/2025

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

2025-521059-21-00Radiographic axial spondyloarthritis (as known as ankylosin…

Merck Sharp & Dohme LLC

Musculoskeletal Diseases

Netherlands, Germany, Poland

30/10/2025

Phase III

Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series

2025-520846-31-00Tuberous Sclerosis Complex (TSC), Sanfilippo syndrome, Frag…

DrugCannabidiol

Amsterdam UMC Stichting

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

30/10/2025

Phase II

An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease

2024-520208-25-00Still’s disease

Novartis Pharma AG

Immune System Diseases

Italy, Netherlands, Spain, France, Germany

28/10/2025

Phase III

Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

2024-514693-47-01EGFR mutated locally advanced or metastatic non-small cell …

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands, Belgium

28/10/2025

Phase I

AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors

Amgen Inc.

Neoplasms

France, Netherlands, Germany, Denmark, Spain, Italy, Belgium

28/10/2025

Phase II

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

2024-517614-14-00Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Immunovant Sciences GmbH

Immune System Diseases

Austria, Hungary, Slovenia, Greece, Denmark, Ireland, Finland, Estonia, Spain, Slovakia, Netherlands, Poland, Norway, Italy, Portugal, Belgium, Germany, Romania, Bulgaria

28/10/2025

Phase III

A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer

2023-507525-42-00Endometrial cancer

BioNTech SE

Female Urogenital Diseases and Pregnancy Complications

Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands

27/10/2025

Phase III

A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis

2025-522946-37-00Familial adenomatous polyposis (FAP)

Biodexa Limited, Rapamycin Holdings Inc.

Virus Diseases

Denmark, Spain, Germany, Netherlands, Italy

27/10/2025

Phase I

Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease.

2025-523254-14-00Parkinson's disease

Vertero Therapeutics Inc.

Nervous System Diseases

Netherlands

27/10/2025

Phase IV

Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients

2025-522111-42-02muscle protein turnover hemodialysis

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Nutritional and Metabolic Diseases

Netherlands

27/10/2025

Phase II

Cityview: PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients with Inflammatory Mediated Immune Disease

2025-522189-60-00Inflammatory mediated immune diseases

Citryll B.V.

Immune System Diseases

Netherlands

24/10/2025

Phase III

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.

2025-521511-40-00metastatic non-small cell lung cancer

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain

24/10/2025

Phase III

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

2025-521398-15-00Immune system diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Netherlands, Spain, France, Belgium, Sweden, Germany, Poland, Italy

24/10/2025

Phase II

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor

2025-520468-16-00Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced U…

Genmab A/S

Neoplasms

France, Spain, Netherlands, Germany

23/10/2025

Phase II

A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

2025-521107-42-00Alzheimer's Disease

Glaxosmithkline Research & Development Limited

Nervous System Diseases

Sweden, Norway, Italy, France, Spain, Finland, Netherlands, Germany

23/10/2025

Phase III

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

2024-513676-18-00Transthyretin Amyloidosis

DrugAcoramidis

Eidos Therapeutics Inc.

Cardiovascular Diseases

Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece

22/10/2025

Phase I

Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants

2025-521402-18-00Desmoid tumor

Springworks Therapeutics Inc.

Skin and Connective Tissue Diseases

Netherlands

22/10/2025

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

2024-514401-54-00Chronic Primary Immune Thrombocytopenia

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France

22/10/2025

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)

2025-520746-30-00Mild to moderate Alzheimer’s Disease

Bristol-Myers Squibb Services Unlimited Company

Mental Disorders

Germany, Croatia, Italy, Poland, Romania, Czechia, Greece, Spain, France, Netherlands

21/10/2025

Phase II

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)

2024-520130-29-00Spinal Muscular Atrophy

Scholar Rock Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Belgium, France, Italy, Spain, Netherlands

21/10/2025

Phase IV

ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery

2025-521385-10-00Breast cancer

DrugTamoxifen

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

21/10/2025

Phase III

2025-520747-32-00Mild to moderate Alzheimer’s Disease

Bristol-Myers Squibb Services Unlimited Company

Mental Disorders

Germany, Netherlands, Portugal, France, Spain, Poland, Greece, Romania, Italy, Finland

21/10/2025

Phase III

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

2024-518365-10-00Previously Untreated Advanced or Metastatic Non-Squamous No…

F. Hoffmann-La Roche AG

Neoplasms

Ireland, Greece, Hungary, Netherlands, France, Denmark, Germany, Poland, Italy, Portugal, Spain, Belgium

21/10/2025

Phase IV

MetAddon: Methadone as co-analgesic for patients with metastatic bone pain: a double-blind randomized controlled trial

2025-522710-22-00Cancer, bone metastasis, pain

Universiteit Maastricht

Neoplasms

Netherlands

20/10/2025

Phase III

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy

2025-521697-34-00Peanut allergy

Dbv Technologies

Immune System Diseases

Spain, France, Netherlands, Ireland

20/10/2025

Phase III

C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…

Pfizer Inc.

Neoplasms

Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy

20/10/2025

Phase II

EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

2024-519960-42-00PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis Pharma AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Italy, Netherlands, Belgium, Spain, Austria, Germany, France

20/10/2025

Phase II

EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial

2024-520433-76-00Newly Diagnosed Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab

European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale

Neoplasms

Norway, Italy, Spain, Netherlands

20/10/2025

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

2025-521920-31-00Graves’ Disease

Immunovant Sciences GmbH

Immune System Diseases

Italy, Poland, Greece, Germany, Netherlands, Czechia, Spain, Latvia, Bulgaria

17/10/2025

Phase I

Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants

2025-522935-32-00interstitial cystitis/bladder pain syndrome

Dompe' Farmaceutici S.p.A.

Pathological Conditions, Signs and Symptoms

Netherlands

17/10/2025

Phase II

A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation

2024-520375-27-00Lower respiratory tract viral infections

Synairgen Research Limited

Virus Diseases

Netherlands, France, Spain, Belgium

15/10/2025

Phase III

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).

2024-516906-47-00Locally Advanced or Metastatic Urothelial Carcinoma

DrugsDato-DXd·Cisplatin·Carboplatin

Daiichi Sankyo Inc.

Neoplasms

Netherlands, Germany, Norway, Denmark, France, Austria, Italy, Spain, Belgium, Czechia, Greece

15/10/2025

Phase I

Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial

2025-522128-28-00Breast cancer, Non small cell lung carcinoma, Glioblastoma

Amsterdam UMC Stichting

Neoplasms

Netherlands

15/10/2025

Phase I

A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS

2025-521876-77-00Cholestatic liver disease

ProQR Therapeutics VIII B.V.

Nutritional and Metabolic Diseases

Netherlands

14/10/2025

Phase III

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

2024-519917-72-00Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloid…

Alnylam Pharmaceuticals Inc.

Cardiovascular Diseases

France, Germany, Italy, Greece, Belgium, Portugal, Netherlands, Austria, Sweden, Denmark, Spain, Czechia, Hungary, Ireland, Romania, Norway, Poland, Slovakia

14/10/2025

Phase III

J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)

2025-521067-13-00Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASC…

Eli Lilly & Co.

Cardiovascular Diseases

Italy, Poland, Germany, Austria, Romania, Spain, Czechia, France, Denmark, Greece, Hungary, Slovakia, Belgium, Netherlands

13/10/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

Clinical Trials in Netherlands, 2026

Trials with a site in Netherlands

About this register

How many recently authorised EU trials have a site in Netherlands?

Summary by phase

Most active sponsors

Phase	Trials	Share
Phase III	238	42.9%
Phase II	135	24.3%
Phase I	102	18.4%
Phase I/II	48	8.6%
Phase IV	32	5.8%